ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pollution

Crystal structure shows LSD bound to its receptor

The psychedelic molecule could help treat depression

by Ariana Remmel
September 19, 2020 | APPEARED IN VOLUME 98, ISSUE 36

 

09836-scicon4-lsd.jpg
Credit: Cell
This new crystal structure shows LSD (red) bound to its target serotonin receptor.

Psychedelic drugs such as lysergic acid diethylamide (LSD) show promise in the treatment of depression and substance abuse disorders, but chemists still don’t know how they work at a molecular level. Now, a team led by Bryan Roth, a molecular pharmacologist at the University of North Carolina at Chapel Hill School of Medicine, has produced the first crystal structure of a psychedelic compound bound to its receptor in the active state. Using X-ray crystallography and cryo-electron microscopy, the researchers determined the structures of LSD and other hallucinogenic compouds bound to the 5-HT2A serotonin receptor (HTR2A) (Cell 2020, DOI: 10.1016/j.cell.2020.08.024). These protein structures show how the molecules “dive into the core of the receptor and cause a tryptophan residue to be dislocated extensively—more than we had ever imagined,” Roth says. “It gives us the first molecular insights into psychedelic drug action.” The team is developing tools to screen new drug candidates for their ability to activate the receptor without causing hallucinogenic side effects.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment